Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Assets for 7 consecutive years, with $424.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets fell 29.81% to $424.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $424.0 million, a 29.81% decrease, with the full-year FY2024 number at $560.4 million, up 64.87% from a year prior.
  • Assets was $424.0 million for Q3 2025 at 4D Molecular Therapeutics, down from $473.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $629.9 million in Q1 2024 to a low of $240.6 million in Q3 2021.
  • A 5-year average of $390.3 million and a median of $352.5 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: soared 158.13% in 2024, then dropped 29.81% in 2025.
  • 4D Molecular Therapeutics' Assets stood at $353.5 million in 2021, then fell by 25.92% to $261.8 million in 2022, then grew by 29.81% to $339.9 million in 2023, then skyrocketed by 64.87% to $560.4 million in 2024, then decreased by 24.34% to $424.0 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Assets are $424.0 million (Q3 2025), $473.6 million (Q2 2025), and $515.7 million (Q1 2025).